Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.

Danielle ShaferAmanda B KaganMichelle A RudekMaciej KmieciakMary Beth TombesEllen ShraderDipankar BandyopadhyayDaniel HudsonHeidi SankalaCaryn WeirJeffrey E LancetSteven Grant

Published in: Cancer chemotherapy and pharmacology (2023)

The combination of belinostat and adavosertib at the tested dose levels was feasible but without efficacy signals in the relapsed/refractory MDS/AML population.

Keyphrases

acute myeloid leukemia
acute lymphoblastic leukemia
allogeneic hematopoietic stem cell transplantation
multiple myeloma
hodgkin lymphoma
diffuse large b cell lymphoma
open label
dendritic cells
clinical trial
immune response